← Back to Search

Other

129Xe Imaging for Pulmonary Arterial Hypertension (Sox-PH Trial)

Phase 2
Waitlist Available
Led By Sudarshan Rajagopal, MD, PhD
Research Sponsored by Bastiaan Driehuys
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to see if a special type of MRI/MRS scan using 129Xe can help track changes in the blood vessels in the lungs of people with PAH who are receiving sot

Who is the study for?
This trial is for patients with Pulmonary Arterial Hypertension (PAH), a type of high blood pressure affecting the lungs. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have a confirmed diagnosis of PAH.
What is being tested?
The study is testing how well a special type of lung imaging called '129 Xenon Imaging' can track changes in the lungs caused by Sotatercept treatment in PAH patients. This involves using MRI/MRS technology to create detailed images.
What are the potential side effects?
Potential side effects are not listed for this specific procedure, but generally, MRI/MRS scans are considered safe. There might be risks related to inhaling hyperpolarized xenon gas used during imaging; however, these should be minimal.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pulmonary Arterial Hypertension Patients Receving SotaterceptExperimental Treatment1 Intervention
PAH patients receiving sotatercept as treatment for their PAH

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
4,015 Previous Clinical Trials
5,186,319 Total Patients Enrolled
12 Trials studying Pulmonary Arterial Hypertension
997 Patients Enrolled for Pulmonary Arterial Hypertension
Bastiaan DriehuysLead Sponsor
14 Previous Clinical Trials
1,067 Total Patients Enrolled
4 Trials studying Pulmonary Arterial Hypertension
110 Patients Enrolled for Pulmonary Arterial Hypertension
Sudarshan Rajagopal, MD, PhDPrincipal InvestigatorDuke University
4 Previous Clinical Trials
116 Total Patients Enrolled
2 Trials studying Pulmonary Arterial Hypertension
90 Patients Enrolled for Pulmonary Arterial Hypertension
~9 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top